Status:
TERMINATED
Efficacy of Bifeprunox in Patients With Schizophrenia
Lead Sponsor:
H. Lundbeck A/S
Conditions:
Schizophrenia
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
The primary purpose of the study is to evaluate the efficacy of bifeprunox in the maintenance phase of schizophrenia compared to placebo.
Detailed Description
Schizophrenia is a serious and disabling mental disorder that affects approximately 1% of the world's population. There are a number of antipsychotic drugs in use but none is ideal, in particular beca...
Eligibility Criteria
Inclusion
- Main inclusion criteria
- The subject has a primary diagnosis of schizophrenia
- The subject experiences clinically significant symptoms
- The subject's medication remained stable for 8 weeks prior to screening
- The subject is currently in the post-acute maintenance phase of his/her disease
Exclusion
- Main exclusion criteria
- The subject is at significant risk of suicide
- The subject is treatment resistant
- The subject has experienced an acute exacerbation within 8 weeks prior screening
- The subject is unlikely to comply with the protocol
- The subject has a current diagnosis or a history of substance abuse
Key Trial Info
Start Date :
June 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2009
Estimated Enrollment :
346 Patients enrolled
Trial Details
Trial ID
NCT00704509
Start Date
June 1 2008
End Date
November 1 2009
Last Update
September 27 2010
Active Locations (45)
Enter a location and click search to find clinical trials sorted by distance.
1
IN008
Ahmedabad, India, 380006
2
IN011
Ahmedabad, India, 380013
3
IN009
Aurangabad, India, 431005
4
IN003
Bangalore, India, 560002